<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04667572</url>
  </required_header>
  <id_info>
    <org_study_id>PXL-330-CAT-2</org_study_id>
    <nct_id>NCT04667572</nct_id>
  </id_info>
  <brief_title>Safety &amp; Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution</brief_title>
  <official_title>Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Collagen Cross-Linking in Eyes With Corneal Thinning Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cornea Associates of Texas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cornea Associates of Texas</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Collagen Cross-linking in&#xD;
      Eyes With Corneal Thinning Conditions&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with progressive keratoconus, pellucid marginal degeneration, or at risk for&#xD;
      post-refractive corneal ectasia will be recruited and undergo epithelial-on corneal&#xD;
      crosslinking with the Peschke PXL-330 system using pulsed, accelerated energy delivery.&#xD;
      Patients will undergo monitoring for 1 year, with serial measurements of corneal topography,&#xD;
      visual acuity, pachymetry, and visual function.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>K-Max</measure>
    <time_frame>12 Months</time_frame>
    <description>Change in K-Max measured by corneal topography, compared to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>K-Mean</measure>
    <time_frame>12 Months</time_frame>
    <description>Change in K-Mean measured by corneal topography, compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uncorrected Visual Acuity</measure>
    <time_frame>12 Months</time_frame>
    <description>Change in uncorrected corrected visual acuity using snellen measurements, compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity</measure>
    <time_frame>12 Months</time_frame>
    <description>Change in best corrected visual acuity using snellen measurements, compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Pachymetry</measure>
    <time_frame>12 Months</time_frame>
    <description>Change in central pachymetry, measured by Pentacam compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Keratoconus</condition>
  <condition>Pellucid Marginal Corneal Degeneration</condition>
  <condition>Corneal Degeneration</condition>
  <condition>Corneal Ectasia</condition>
  <arm_group>
    <arm_group_label>Pulsed 5mW/cm2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5mW/cm2, with pulsed mode, 10 seconds on, 10 second off, for 36 minute total treatment time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulsed 8mW/cm2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8mW/cm2, with pulsed mode, 10 seconds on, 10 second off, for 22 minute and 30 seconds total treatment time</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>PXL-330 Platinum device for crosslinking with Peschke riboflavin solution</intervention_name>
    <description>Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea</description>
    <arm_group_label>Pulsed 5mW/cm2</arm_group_label>
    <arm_group_label>Pulsed 8mW/cm2</arm_group_label>
    <other_name>Corneal Crosslinking</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  8 years of age or older&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  Willingness and ability to comply with schedule for follow-up visits&#xD;
&#xD;
          -  Contact Lens Wearers Only:&#xD;
&#xD;
          -  Removal of contact lenses (if applicable) for the required period of time prior to the&#xD;
             screening refraction: Soft, discontinue 3 days; Soft Extended Wear, discontinue 3&#xD;
             days; Soft Toric, discontinue 3 days; Rigid gas permeable, discontinue 2 Weeks&#xD;
             (subjects who cannot function without wearing their contact lenses, may forgo&#xD;
             discontinuation of contact lenses)&#xD;
&#xD;
        And one or more of the following:&#xD;
&#xD;
          -  Presence of central or inferior steepening.&#xD;
&#xD;
          -  Axial topography consistent with keratoconus, post-surgical ectasia, or pellucid&#xD;
             marginal degeneration&#xD;
&#xD;
          -  Presence of one or more findings associated with keratoconus or pellucid marginal&#xD;
             degeneration, such as: Fleischer ring, Vogt's striae, Decentered corneal apex,&#xD;
             Munson's sign, Rizzutti's sign, Apical Corneal scarring consistent with Bowman's&#xD;
             breaks, Scissoring of the retinoscopic reflex, Crab-claw appearance on topography&#xD;
&#xD;
          -  Steepest keratometry (Kmax) value â‰¥ 47.20 D&#xD;
&#xD;
          -  I-S keratometry difference &gt; 1.5 D on the Pentacam/Orbscan map or topography map&#xD;
&#xD;
          -  Posterior corneal elevation &gt;16 microns&#xD;
&#xD;
          -  Thinnest corneal point &gt;300 microns&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Eyes classified as either normal or atypical normal on the severity grading scheme.&#xD;
&#xD;
          -  Corneal thickness &lt; 300 microns measured by ultrasonic pachymetry or pentacam.&#xD;
&#xD;
          -  Previous ocular condition (other than refractive error) in the eye(s) to be treated&#xD;
             that may predispose the eye for future complications, for example: History of or&#xD;
             active corneal disease (e.g., herpes simplex, herpes zoster keratitis, recurrent&#xD;
             erosion syndrome, etc.) Clinically significant corneal scarring in the CXL treatment&#xD;
             zone that is not related to keratoconus or, in the investigator's opinion, will&#xD;
             interfere with the cross-linking procedure.&#xD;
&#xD;
          -  Pregnancy (including plan to become pregnant) or lactation during the course of the&#xD;
             study&#xD;
&#xD;
          -  A known sensitivity to study medications&#xD;
&#xD;
          -  Patients with nystagmus or any other condition that would prevent a steady gaze during&#xD;
             the CXL treatment or other diagnostic tests.&#xD;
&#xD;
          -  Patients with a current condition that, in the physician's opinion, would interfere&#xD;
             with or prolong epithelial healing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jennifer Seale, COT</last_name>
    <phone>12146920146</phone>
    <phone_ext>131</phone_ext>
    <email>jseale@corneatexas.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tyrone McCall, MD</last_name>
    <phone>12146920146</phone>
    <email>tyrone.mccall@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cornea Associates of Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tyrone McCall, MD</last_name>
      <phone>214-692-0146</phone>
      <email>tmccall@corneatexas.com</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Seale, COT</last_name>
      <phone>214-692-0146</phone>
      <email>jseale@corneatexas.com</email>
    </contact_backup>
    <investigator>
      <last_name>Tyrone McCall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Walter E Beebe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles B Bowman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gregory Nettune, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joshua Zaffos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jamie Alexander, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luke Potts, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 2, 2020</study_first_submitted>
  <study_first_submitted_qc>December 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2020</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
    <mesh_term>Corneal Dystrophies, Hereditary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

